Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 151 - 160 of 243
Alternative Name: Biodegradable Norethindrone (NET) Pellets
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Anterion Therapeutics, FHI 360
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Lavax Vaginal Suppository
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Developer: Lavax
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Male
Hormonal: No
Delivery Method: Oral
Developer: North Shore University Hospital in New York
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: Nomegestrol acetate (NOMAC) vaginal ring
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Developer: Merck
Development Stage: Prototype Development
Development Phase: Discovery and Early Development
Alternative Name: Non-Invasive Laser Male Sterilization
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Vas Deferens
Developer: University of North Carolina at Charlotte
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Allergan
Development Stage: Regulatory
Development Phase: Limited Market Availability
User: Female, Male
Duration Type: Short-acting, Pericoital
Delivery Method: Injectable, Vaginal, Other, Other
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: Woman's Condom (WC)
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Shanghai Dahua Medical Apparatus Co., Ltd, PATH
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
Alternative Name: Oil-based drospirenone (DSRP) microcrystal suspension
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Bayer HealthCare
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Male
Hormonal: No
Delivery Method: Oral
Developer: South African Medical Research Council, University of Western Cape
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 21 - 30 of 70
User: Male
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Vas Deferens
Developer: National Research Institute for Family Planning in Beijing
Development Stage: Prototype Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Other
Development Stage: Lead Optimization
Alternative Name: Inhibition of Vas Propulsive Contractility
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: King's College, London
Development Stage: Lead Optimization
Alternative Name: K4K20S4
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other, Other
Development Stage: Lead Optimization
Alternative Name: Plasma Membrane Calcium ATPase (PMCA) Inhibitors
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Gel, Vaginal, Other
Developer: University of Manchester, Max Planck Institute
Alternative Name: Electrospun fiber meshes
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Development Stage: Prototype Development
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Vas Deferens
Developer: Contraline, LLC
Development Stage: Lead Optimization
User: Male
Hormonal: No
Developer: Eppin Pharma, Inc.
Development Stage: Lead Optimization
Alternative Name: Epididymal Peptidase Inhibitor
Target
User: Male
Hormonal: No
Developer: Eppin Pharma, Inc.
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Evestra, Inc.
Development Stage: Prototype Development

Pages

Displaying 101 - 110 of 121
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR)
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: FHI 360
Development Stage: Phase I
Alternative Name: Hormonal Intrauterine Ball
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: OCON Medical Ltd.
Development Stage: Pre-clinical
Alternative Name: NSP-989; NSP-989 COMBO; Tanaproget COMBO; WAY-166989
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Ligand Pharmaceuticals, Inc.
Development Stage: Phase II
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Alternative Name: Tenofovir Disoproxil Fumarate (TDF) + Levonorgestrel Vaginal Ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Albert Einstein College of Medicine, NIAID, Northwestern University
Development Stage: Phase I
Alternative Name: Testicular heat supplementation
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Testicular
Developer: University of California at Los Angeles
Development Stage: Phase II
User: Male
Hormonal: No
Duration Type: Permanent, Short-acting
Delivery Method: Testicular
Developer: Parsemus Foundation, University of Bari, University of California, University of North Carolina at Chapel Hill
Development Stage: Pre-clinical
Alternative Name: TU; Aveed
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Bayer HealthCare, National Research Institute for Family Planning in Beijing
Development Stage: Phase III
Alternative Name: TV-46046
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Teva Branded Pharmaceutical Products R&D, Inc.
Development Stage: Phase I

Pages

Displaying 21 - 30 of 52
Alternative Name: GyneFix 330
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shenyang Liren Medical & Technological Co.
Development Stage: Marketed
Alternative Name: Copper IUD for Nulliparous Women, Smaller Copper IUD T380
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Implementos Plasticos, Ltd., Mexico City
Development Stage: SRA/WHO PQ Approved
Alternative Name: SCu300 Intrauterine Devices, empira™
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: OCON Medical Ltd.
Development Stage: SRA/WHO PQ Approved
Alternative Name: LNG Contraceptive IUS (LCS); LCS16
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Bayer HealthCare
Development Stage: SRA/WHO PQ Approved
Alternative Name: Zarin; Femplant; Trust; Sino-implant (II)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: FHI 360, Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Marketed
Alternative Name: Levosert (U.K.); Erlacela (Portugal); Donasert (Romania); Avibela
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Actavis, Medicines360
Development Stage: SRA/WHO PQ Approved
Alternative Name: FC-Patch Low; Gestodene (GES) + ethinyl estradiol (EE) Patch
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: WHO HRP, Bayer HealthCare, Gedeon Richter Plc.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: Regulatory
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Mona Lisa N.V.
Development Stage: SRA/WHO PQ Approved

Pages

CSV